---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-001172"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2021-08-10T23:59:59+00:00"
generated_at: "2026-06-29T17:13:53.042474+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Janux Therapeutics Q2 net loss $6.2M; cash $394.2M post $222.9M IPO

## Summary
- Completed $222.9M IPO in June and $125.0M Series B in April, total $347.9M in quarter.
- Cash and short-term investments of $394.2M at June 30, 2021 vs $7.8M at Dec 31, 2020.
- Q2 net loss of $6.2M, compared to $2.5M in same period 2020; R&D expense $4.7M.
- On track to submit at least two INDs by end of 2022 for lead TRACTr programs.
- Appointed Shahram Salek-Ardakani as CSO and Wayne Godfrey as CMO.

## SEC filing metadata
- accession: 0000950170-21-001172
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2021-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017021001172/0000950170-21-001172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017021001172/janx-20210810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-001172
- JSON: https://secwatch.observer/filing/0000950170-21-001172.json
- Plain text: https://secwatch.observer/filing/0000950170-21-001172.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.